NCT06906198View on ClinicalTrials.gov

Pharmacokinetics of VVN461 Ophthalmic Solution

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

March 1, 2023

Primary Completion Date

May 10, 2023

Study Completion Date

December 22, 2023

Conditions
Healthy Volunteers
Interventions
DRUG

VVN461 Ophthalmic Solution 1.0%

VVN461, 1.0%

DRUG

VVN461 Ophthalmic Solution 0.5%

VVN461, 0.5%

DRUG

VVN461 Ophthalmic Solution 0.25%

VVN461, 0.25%

DRUG

VVN461 Ophthalmic Solution Placebo

Vehicle

Trial Locations (1)

325027

Eye Hospital of Wenzhou Medical University, Wenzhou

All Listed Sponsors
lead

VivaVision Biotech, Inc

INDUSTRY